Consun Pharmaceutical Group (HKG:1681) reported a 16.1% increase in profit attributable to equity shareholders for 2024 to 910.5 million yuan from 784.5 million yuan a year earlier, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share were 1.09 yuan, an 11.2% increase from 0.98 yuan the previous year.
Revenue increased by 14.6% to 2.97 billion yuan from 2.59 billion yuan in the prior year.
The board recommended a final dividend of HK$0.30 per share.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。